{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:18:21Z","timestamp":1767183501105,"version":"build-2065373602"},"reference-count":67,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>OnabotulinumtoxinA (BoNT-A) was first used to treat neurogenic lower urinary tract dysfunction (LUTD) 30 years ago. Recently, application of BoNT-A in LUTD have become more common since the approval of intravesical BoNT-A injection for patients with both overactive bladders (OAB) and neurogenic detrusor overactivity (NDO) by regulatory agencies in many countries. Although unlicensed, BoNT-A has been recommended to treat patients with interstitial cystitis\/bladder pain syndrome (IC\/BPS) under different guidelines. BoNT-A delivery with liposome-encapsulation and gelation hydrogel intravesical instillation provided a potentially less invasive and more convenient form of application for patients with OAB or IC\/BPS. BoNT-A injections into the urethral sphincter for spinal cord injury patients with detrusor-sphincter dyssynergia have been used for a long time. New evidence revealed that it could also be applied to patients with non-neurogenic dysfunctional voiding. Previous studies and meta-analyses suggest that BoNT-A injections for patients with benign prostate hyperplasia do not have a better therapeutic effect than placebo. However, new randomized and placebo-controlled trials revealed intraprostatic BoNT-A injection is superior to placebo in specific patients. A recent trial also showed intraprostatic BoNT-A injection could significantly reduce pain in patients with chronic prostatitis. Both careful selection of patients and prudent use of urodynamic evaluation results to confirm diagnoses are essential for successful outcomes of BoNT-A treatment for LUTD.<\/jats:p>","DOI":"10.3390\/toxins10070260","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T10:40:50Z","timestamp":1530009650000},"page":"260","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction"],"prefix":"10.3390","volume":"10","author":[{"given":"Jia-Fong","family":"Jhang","sequence":"first","affiliation":[{"name":"Department of Urology, Buddhist Tzu Chi General Hospital, and Tzu Chi University, Hualien 970, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-4771","authenticated-orcid":false,"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Urology, Buddhist Tzu Chi General Hospital, and Tzu Chi University, Hualien 970, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.juro.2016.01.007","article-title":"Symptoms of lower urinary tract dysfunction research network","volume":"196","author":"Yang","year":"2016","journal-title":"J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00192-015-2626-8","article-title":"Prevalence, risk factors and the bother of lower urinary tract symptoms in China: A population-based survey","volume":"26","author":"Wang","year":"2015","journal-title":"Int. Urogynecol. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.coph.2004.12.006","article-title":"Botulinal neurotoxins: Revival of an old killer","volume":"5","author":"Montecucco","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.53.8.1850","article-title":"Historical aspects of botulinum toxin: Justinus Kerner (1786\u20131862) and the \u201csausage poison\u201d","volume":"53","author":"Erbguth","year":"1999","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/0019-5154.60343","article-title":"Botulinum toxin","volume":"55","author":"Nigam","year":"2010","journal-title":"Indian J. Dermatol."},{"key":"ref_6","first-page":"734","article-title":"Botulinum toxin injection of eye muscles to correct strabismus","volume":"79","author":"Scott","year":"1981","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","article-title":"Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients","volume":"139","author":"Dykstra","year":"1988","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","article-title":"Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment","volume":"193","author":"Hanno","year":"2015","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7192","DOI":"10.1128\/AEM.70.12.7192-7199.2004","article-title":"Differentiation of the gene clusters encoding botulinum neurotoxin type a complexes in clostridium botulinum type a, ab, and a(b) strains","volume":"70","author":"Franciosa","year":"2004","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2011.11.001","article-title":"Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain","volume":"12","author":"Dolly","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxicon.2015.09.009","article-title":"The long journey of botulinum neurotoxins into the synapse","volume":"107","author":"Rummel","year":"2015","journal-title":"Toxicon"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1091\/mbc.e08-01-0010","article-title":"A role for soluble N-ethylmaleimide-sensitive factor attachment protein receptor complex dimerization during neurosecretion","volume":"19","author":"Fdez","year":"2008","journal-title":"Mol. Biol. Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","article-title":"Evidence for antinociceptive activity of botulinum toxin type A in pain management","volume":"43","author":"Aoki","year":"2003","journal-title":"Headache"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.36076\/ppj.2013\/16\/291","article-title":"Central sensitization in urogynecological chronic pelvic pain: A systematic literature review","volume":"16","author":"Kaya","year":"2013","journal-title":"Pain Phys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1464-410X.2012.11466.x","article-title":"Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis\/bladder pain syndrome","volume":"111","author":"Shie","year":"2013","journal-title":"BJU Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"21","author":"Haylen","year":"2010","journal-title":"Int. Urogynecol. J."},{"key":"ref_19","unstructured":"Chuang, Y.C., Liu, S.P., Lee, K.S., Liao, L., Wang, J., Yoo, T.K., Chu, R., and Sumarsono, B. (2017). Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study. Low Urin. Tract Symptoms."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sc.2013.19","article-title":"Neurogenic detrusor overactivity in adults: A review on efficacy, tolerability and safety of oral antimuscarinics","volume":"51","author":"Madersbacher","year":"2013","journal-title":"Spinal Cord"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/sc.2014.113","article-title":"Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients?","volume":"52","author":"Hadiji","year":"2014","journal-title":"Spinal Cord"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.22445","article-title":"Targets for botulinum toxin in the lower urinary tract","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.urology.2012.12.021","article-title":"Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: A single-blind study","volume":"81","author":"Priefert","year":"2013","journal-title":"Urology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1152\/physrev.00038.2003","article-title":"Urinary bladder contraction and relaxation: Physiology and pathophysiology","volume":"84","author":"Andersson","year":"2004","journal-title":"Physiol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2015.07.071","article-title":"Summary of European Association of Urology (EAU) guidelines on neuro-urology","volume":"69","author":"Groen","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.juro.2016.11.092","article-title":"Past, Present and future of chemodenervation with botulinum toxin in the treatment of overactive bladder","volume":"197","author":"Tyagi","year":"2017","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/nau.23196","article-title":"Long-term compliance and results of intravesical botulinum toxin A injections in male patients","volume":"36","author":"Rahnamai","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.juro.2017.05.068","article-title":"Long-Term treatment with onabotulinumtoxina results in consistent, durable improvements in health related quality of life in patients with overactive bladder","volume":"198","author":"Ginsberg","year":"2017","journal-title":"J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.eururo.2014.01.036","article-title":"Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: A single-center study","volume":"65","author":"Kuo","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5213\/inj.2015.19.3.185","article-title":"Underactive bladder: Clinical features, urodynamic parameters, and treatment","volume":"19","author":"Hoag","year":"2015","journal-title":"Int. Neurourol. J."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wang, C.C., Lee, C.L., and Kuo, H.C. (2016). Efficacy and safety of intravesical onabotulinumtoxina injection in patients with detrusor hyperactivity and impaired contractility. Toxins, 8.","DOI":"10.3390\/toxins8030082"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2011.03.132","article-title":"Prevalence of symptoms of bladder pain syndrome\/interstitial cystitis among adult females in the United States","volume":"186","author":"Berry","year":"2011","journal-title":"J. Urol."},{"key":"ref_35","first-page":"83","article-title":"Treating interstitial cystitis\/bladder pain syndrome as a chronic disease","volume":"16","author":"Bosch","year":"2014","journal-title":"Rev. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.urology.2004.06.073","article-title":"Botulinum toxin a has antinociceptive effects in treating interstitial cystitis","volume":"64","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/nau.22760","article-title":"Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis\/bladder pain syndrome refractory to conventional treatment\u2014A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial","volume":"35","author":"Kuo","year":"2016","journal-title":"Neurourol. Urodyn."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3390\/toxins7062232","article-title":"Novel treatment of chronic bladder pain syndrome and other pelvic pain disorders by onabotulinumtoxina injection","volume":"7","author":"Jhang","year":"2015","journal-title":"Toxins"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00192-016-3079-4","article-title":"Intravesical treatment for interstitial cystitis\/painful bladder syndrome: A network meta-analysis","volume":"28","author":"Zhang","year":"2017","journal-title":"Int. Urogynecol. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.juro.2017.02.021","article-title":"A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxina for interstitial cystitis\/bladder pain syndrome","volume":"198","author":"Chuang","year":"2017","journal-title":"J. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2017.12.028","article-title":"Safety and feasibility of intravesical instillation of botulinum toxin-a in hydrogel-based slow-release delivery system in patients with interstitial cystitis-bladder pain syndrome: A pilot study","volume":"114","author":"Rappaport","year":"2018","journal-title":"Urology"},{"key":"ref_42","first-page":"195","article-title":"Detrusor-external sphincter dyssynergia","volume":"151","author":"Chancellor","year":"1990","journal-title":"Ciba Found. Symp."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Jhang, J.F., and Kuo, H.C. (2016). Botulinum toxin a and lower urinary tract dysfunction: Pathophysiology and mechanisms of action. Toxins, 8.","DOI":"10.3390\/toxins8040120"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/nau.20606","article-title":"Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion","volume":"27","author":"Kuo","year":"2008","journal-title":"Neurourol. Urodyn."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2340\/16501977-2132","article-title":"Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia","volume":"48","author":"Huang","year":"2016","journal-title":"J. Rehabil. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrurol.2013.277","article-title":"Fowler\u2019s syndrome\u2014A cause of unexplained urinary retention in young women?","volume":"11","author":"Osman","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bju.13342","article-title":"Open-label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler\u2019s syndrome)","volume":"117","author":"Panicker","year":"2016","journal-title":"BJU Int."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Jiang, Y.H., Wang, C.C., and Kuo, H.C. (2016). OnabotulinumtoxinA urethral sphincter injection as treatment for non-neurogenic voiding dysfunction\u2014A randomized, double-blind, placebo-controlled study. Sci. Rep., 6.","DOI":"10.1038\/srep38905"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Wang, W., Guo, Y., Zhang, D., Tian, Y., and Zhang, X. (2015). The prevalence of benign prostatic hyperplasia in mainland China: Evidence from epidemiological surveys. Sci. Rep., 5.","DOI":"10.1038\/srep13546"},{"key":"ref_50","first-page":"S14","article-title":"Pressure flow urodynamic studies: The gold standard for diagnosing bladder outlet obstruction","volume":"7","author":"Nitti","year":"2005","journal-title":"Rev. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"J. Urol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/pros.2990250204","article-title":"Smooth muscle contractility in prostatic hyperplasia: Role of cyclic adenosine monophosphate","volume":"25","author":"Drescher","year":"1994","journal-title":"Prostate"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.urology.2005.04.029","article-title":"Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates","volume":"66","author":"Chuang","year":"2005","journal-title":"Urology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0090-4295(03)00477-1","article-title":"Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study","volume":"62","author":"Maria","year":"2003","journal-title":"Urology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S0022-5347(05)00318-6","article-title":"Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland","volume":"175","author":"Chuang","year":"2006","journal-title":"J. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.juro.2014.02.004","article-title":"A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"192","author":"McVary","year":"2014","journal-title":"J. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","article-title":"A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia","volume":"63","author":"Marberger","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11255-015-1153-3","article-title":"Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: A systematic review and meta-analysis","volume":"48","author":"Shim","year":"2016","journal-title":"Int. Urol. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/nau.23390","article-title":"Intraprostatic botulinum toxin type \u201cA\u201d injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation","volume":"37","author":"Totaro","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2012.10.042","article-title":"National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis\/chronic pelvic pain syndrome","volume":"63","author":"Wagenlehner","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bju.13101","article-title":"Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis\/chronic pelvic pain syndrome: A consensus guideline","volume":"116","author":"Rees","year":"2015","journal-title":"BJU Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(05)79580-5","article-title":"Relief by botulinum toxin of voiding dysfunction due to prostatitis","volume":"352","author":"Maria","year":"1998","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2006.11.037","article-title":"Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A","volume":"51","author":"Chuang","year":"2007","journal-title":"Eur. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bju.12951","article-title":"Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis\/chronic pelvic pain syndrome: Results of a prospective pilot double-blind and randomized placebo-controlled study","volume":"116","author":"Falahatkar","year":"2015","journal-title":"BJU Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.aju.2015.01.001","article-title":"Intraprostatic injection of botulinum toxin-A in patients with refractory chronic pelvic pain syndrome: The transurethral vs. transrectal approach","volume":"13","author":"Tawfik","year":"2015","journal-title":"Arab J. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bju.13025","article-title":"Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder","volume":"116","author":"Malde","year":"2015","journal-title":"BJU Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1442-2042.2008.02016.x","article-title":"Botulinum neurotoxin type A in urology: Antibodies as a cause of therapy failure","volume":"15","author":"Bigalke","year":"2008","journal-title":"Int. J. Urol."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/7\/260\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:10:10Z","timestamp":1760195410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/7\/260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":67,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7]]}},"alternative-id":["toxins10070260"],"URL":"https:\/\/doi.org\/10.3390\/toxins10070260","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2018,6,26]]}}}